#USA #New York #Rosen Law Firm #Soleno Therapeutics #SLNO

Rosen Law Firm Investigates Soleno Therapeutics

In a recent development regarding Soleno Therapeutics, Inc. (NASDAQ: SLNO), the Rosen Law Firm has initiated an investigation focused on potential securities claims aimed at safeguarding the interests of investors. This inquiry comes in the wake of claims suggesting that Soleno may have disseminated materially misleading business information to the investing community.

The Background of the Investigation

The impetus for the Rosen Law Firm’s investigation stems from an article published by Investing.com on August 15, 2025. This piece highlighted the decline of Soleno Therapeutics' stock following a short report issued by Scorpion Capital. The report raised serious concerns about the company's recently launched treatment for Prader-Willi syndrome, known as VYKAT XR, and indicated possible personal safety risks associated with the drug. Notably, the report suggested that VYKAT XR could potentially face market withdrawal or significant drop in new prescriptions.

In response to this revelation, Soleno’s stock plummeted by 7.4% on the same day of the report’s release, and further dipped 4.9% in the subsequent trading session. This significant loss of value has compelled the Rosen Law Firm to take action and offers investors a pathway to seek compensation without incurring any out-of-pocket fees through a contingency fee arrangement.

What This Means for Investors

For those who purchased securities of Soleno Therapeutics, the firm encourages you to join the prospective class action aimed at recovering investor losses. Investors can take action by visiting the Rosen Law Firm’s website or reaching out directly to the firm for more information. Specifically, you can submit your details through their online form here or contact Phillip Kim, Esq. at 866-767-3653 for further guidance.

The Importance of Selecting Qualified Legal Counsel

It is crucial for investors to engage experienced legal representation with a proven track record in handling securities class actions. The Rosen Law Firm emphasizes the importance of selecting counsel that possesses the necessary resources and expertise. Historically, many firms that invite investor participation in class actions lack the litigation experience to effectively support their cases.

The Rosen Law Firm has established itself as a leader in the field, noted for securing substantial settlements, including one of the largest securities class action settlements against a Chinese company, a testament to its efficacy. In addition, the firm has been consistently recognized for its achievements in securing favorable outcomes for investors.

Follow-Up and Future Developments

As the situation evolves, investors are encouraged to follow updates on the Rosen Law Firm’s progress. You can keep track of developments through their social media channels, including LinkedIn, Twitter, and Facebook.

Attorney advertising notices underscore the message that past success does not assure future results. Nevertheless, the firm's robust history inspires confidence among investors looking to reclaim losses stemming from the decline of Soleno Therapeutics’ stock.

For more information or inquiries, you can contact the firm at:

• - Laurence Rosen, Esq.
• - Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Email: [email protected]
Website: www.rosenlegal.com

In conclusion, as investors navigate the complexities of the stock market, understanding legal rights and recourse through reputable firms like the Rosen Law Firm becomes paramount in the pursuit of justice and recovery of losses.